Imagine you go to your doctor for a routine checkup. They offer you a new genetic test that promises to predict your risk for heart disease, diabetes, even cancer. But here’s the catch: if you’re not white, that test might be dangerously wrong. That’s not a hypothetical. It’s the uncomfortable truth about polygenic risk scores (PRS) – a tool hailed as the future of precision medicine.
The very tool designed to personalize your healthcare is actually built on a database that largely ignores you – if you’re not of European descent.
Polygenic risk scores work by comparing your DNA against massive genetic databases to calculate your odds of developing certain diseases. The problem? Those databases are overwhelmingly Eurocentric. According to a study highlighted in the New York Times, a polygenic risk score for breast cancer is 1.5 times more accurate for white women than for Black women. That’s not a margin of error. That’s a life-or-death gap.
This isn’t just a technical glitch. It’s a systemic failure that could widen health disparities for generations. The irony is devastating: a technology meant to fix the ‘one-size-fits-all’ approach of traditional medicine has created a new, more insidious hierarchy – one where your genetic ancestry determines how accurate your risk assessment is.
We’re building a healthcare system that’s precise for some and blind to others – and that’s not progress, it’s a new form of medical apartheid.
You’ve probably noticed how often ‘personalization’ is thrown around in healthcare marketing. It sounds empowering. But the reality is that the data behind the personalization is skewed. The genomic revolution isn’t just a leap in biological engineering; it’s a mirror reflecting centuries of who society chose to study, count, and prioritize in medical history. The same biases that left Black Americans out of clinical trials for decades are now baked into the algorithms that are supposed to save lives.
What can you do? If your doctor ever offers you a polygenic risk score, ask one question: ‘What population is your database based on?’ If the answer is ‘mostly European,’ treat the results with extreme caution. Better yet, demand that your healthcare provider invest in diverse genomic research. Because the future of medicine is coming – and it will either serve everyone, or it will serve only those who already have the most privilege.
The question isn’t whether precision medicine works. It’s whether it works for you.
FAQ
Q: Isn't the lack of diversity just a temporary data collection issue that will be fixed over time?
A: Yes, but only if we actively prioritize diverse genomic research. Without deliberate effort, the bias will persist and even worsen as these tools become standard.
Q: What can I do if I'm not white and my doctor offers a polygenic risk score?
A: Ask your doctor how the test's database was constructed. If it's predominantly European, consider the results with extreme caution. Push for more inclusive research.
Q: Maybe the tool is still useful even for non-Europeans because many genetic risk factors are shared across populations?
A: That's partially true, but the predictive power drops significantly. Relying on a flawed tool can lead to false reassurance or unnecessary alarm. The cost of inaccuracy is too high for individual health decisions.